Clinigen Group plc (AIM: CLIN, ‘Clinigen’ or the ‘Group’), the global pharmaceutical and services company, has appointed Nick Keher Group Chief Financial Officer with effect from 19 March 2019. He will replace Martin Abell, who has resigned and leaves the business on 31 March 2019.
Nick joins from Royal Bank of Canada (RBC) where he was a Managing Director and Head of RBC’s European Healthcare equity research team. He has covered the European healthcare space for over eight years at both RBC and Investec.
Nick started his career at Lloyd’s Pharmacy, registering as a pharmacist before joining GlaxoSmithKline (GSK). At GSK Nick worked within the Group’s R&D, UK Commercial Operations and Global Manufacturing & Supply Strategy finance teams where he trained as an accountant. Nick is a qualified accountant (ACMA) and a qualified pharmacist having completed his Masters degree in Pharmacy, Medicinal Chemistry, Pharmaceuticals, Biology and Maths from Aston University.
Peter Allen, Chairman of Clinigen, said:
“On behalf of the Board and everyone at Clinigen, I would like to thank Martin for his substantial contribution over the last three and a half years. During which time Clinigen has undergone a period of rapid change and development including the acquisitions and integration of Idis, Link, Quantum and CSM, plus a number of products. We wish him every success for the future.”
Shaun Chilton, Group Chief Executive Officer of Clinigen, added:
“Nick brings considerable pharmacy and pharmaceutical experience as well as financial expertise, both as an accountant and from working in the financial markets. He has a deep knowledge and insight of our business through his research and analysis of Clinigen since its IPO in 2012. He will be a key addition to the executive management team.”
The following information is disclosed pursuant to Schedule Two paragraph (g) of the AIM Rules for Companies. Nicholas Patrick Keher, aged 36 years, is not currently a director of any other companies. There is no further information to be disclosed pursuant to Rule 17 or Schedule Two paragraph (g) of the AIM Rules for Companies.
About Clinigen Group
Clinigen Group plc (AIM: CLIN) is a global pharmaceutical and services company with a unique combination of businesses focused on providing ethical access to medicines. Its mission is to deliver the right medicine to the right patient at the right time through three areas of global medicine supply; clinical trial, unlicensed and licensed medicines. The Group has sites in North America, Europe, Africa and Asia Pacific.
Clinical Trial Services
Clinigen is the global market leader in the specialist supply, packaging, distribution and management of quality-assured comparator medicines and services to clinical trials and Investigator Initiated Trials.
Clinigen is the global leader in ethically sourcing and supplying unlicensed medicines to hospital pharmacists and physicians for patients with a high unmet medical need. The Group manages early access programmes to innovative new medicines and provides ‘on demand’ access globally to medicines which remain unlicensed at the point of care.
Clinigen acquires global rights to niche hospital only and critical care products, revitalising these assets around the world and returning them back to sustained growth. It also provides access to licensed and branded generic medicines in the Africa and Asia Pacific region.
The Group also has an ‘unlicensed to licensed’ strategy, where it looks to take unlicensed medicines with commercial potential and licences them, helping to address unmet medical need and allowing the Group to capitalise on its market-leading positions.
For more information on Clinigen, please visit www.clinigengroup.com
Issued for and on behalf of Clinigen by Instinctif Partners.
For more information please contact: email@example.com